Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 OVEREXPRESSION
ERBB2 OVEREXPRESSION
Associated Disease
head and neck squamous cell carcinoma
Source Database
CIViC Evidence
Description
Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases after primary radiochemotherapy. The metastases were analyzed using a commercial molecular analysis and overexpression of HER2 was identified (IHC, 95% of cells, with high intensity 3+ staining) which was confirmed on RNA-level. The patient was treated with single-agent lapatinib. A locally recurrent tumor was excised (and found HER2-negative) and the patient continued on lapatinib (for 2 years) as well as 5 cycles 5-FU and irinotecan. All lung metastases decreased in size within 3 months of lapatinib mono therapy initiation. The patient remains free of local or distant disease 5 years after starting lapatinib.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1992
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/875
Rating
2
Evidence Type
Predictive
Disease
Head And Neck Squamous Cell Carcinoma
Evidence Direction
Supports
Drug
Lapatinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
28061634
Drugs
Drug NameSensitivitySupported
LapatinibSensitivitytrue